Zevra Therapeutics (ZVRA) Revenue & Revenue Breakdown
Zevra Therapeutics Revenue Highlights
Latest Revenue (Y)
$27.46M
Latest Revenue (Q)
$3.69M
Main Segment (Y)
License
Zevra Therapeutics Revenue by Period
Zevra Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $27.46M | 162.58% |
2022-12-31 | $10.46M | -63.50% |
2021-12-31 | $28.65M | 115.61% |
2020-12-31 | $13.29M | 3.50% |
2019-12-31 | $12.84M | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | - |
Zevra Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $3.69M | -16.95% |
2024-06-30 | $4.45M | 29.90% |
2024-03-31 | $3.42M | -74.09% |
2023-12-31 | $13.22M | 356.55% |
2023-09-30 | $2.90M | -65.82% |
2023-06-30 | $8.47M | 194.20% |
2023-03-31 | $2.88M | 24.15% |
2022-12-31 | $2.32M | -19.31% |
2022-09-30 | $2.87M | 121.08% |
2022-06-30 | $1.30M | -67.21% |
2022-03-31 | $3.96M | 53.56% |
2021-12-31 | $2.58M | 31.40% |
2021-09-30 | $1.97M | -83.61% |
2021-06-30 | $11.99M | -1.08% |
2021-03-31 | $12.12M | 412.13% |
2020-12-31 | $2.37M | 22.91% |
2020-09-30 | $1.93M | -72.13% |
2020-06-30 | $6.91M | 230.68% |
2020-03-31 | $2.09M | 51.82% |
2019-12-31 | $1.38M | -88.00% |
2019-09-30 | $11.46M | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | - |
Zevra Therapeutics Revenue Breakdown
Zevra Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 |
---|---|
License | $18.00M |
Latest
Quarterly Revenue by Product
Product/Service | Jun 24 | Mar 24 |
---|---|---|
License | $1.30M | $1.20M |
Latest
Zevra Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AKBA | Akebia Therapeutics | $194.62M | $35.59M |
FBIO | Fortress Biotech | $59.66M | $14.63M |
FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
ZVRA | Zevra Therapeutics | $27.46M | $3.69M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
MOLN | Molecular Partners | $7.04M | $2.74M |
TRVN | Trevena | $3.13M | $325.00K |
STTK | Shattuck Labs | $1.66M | $1.61M |
CCCC | C4 Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
PHVS | Pharvaris | - | - |
RVPH | Reviva Pharmaceuticals | - | - |
PASG | Passage Bio | - | - |
PMVP | PMV Pharmaceuticals | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
FDMT | 4D Molecular Therapeutics | - | - |
RNAZ | TransCode Therapeutics | - | - |
TYRA | Tyra Biosciences | - | - |